Cardiovascular diseases (CVD) remain the major cause of death and premature disability in Western societies. Assessing the risk of CVD is an important aspect in clinical decision-making. Among the growing number of molecules that are studied for their potential utility as CVD biomarkers, a lot of attention has been focused on osteoprotegerin (OPG) and its ligands, which are receptor activator of nuclear factor \u3baB ligand (RANKL) and TNF-related apoptosis-inducing ligand. Based on the existing literature and on our experience in this field, here we review what the possible roles of OPG and TRAIL in CVD are and their potential utility as CVD biomarkers
Background—Osteoprotegerin (OPG) is a secretory glycoprotein that belongs to the tumor necrosis fact...
Osteoprotegerin (OPG), receptor activator of nuclear factor-?B ligand (RANKL) and tumor necrosis fac...
PubMed: 22727437The aim of our study was to investigate whether osteoprotegerin (OPG) is related to ...
Osteoprotegerin (OPG) is a glycoprotein that acts as a decoy receptor for receptor activator of nucl...
Osteoprotegerin (OPG) is a 401 amino acid N-glycosylated protein, which is highly expressed in a lar...
Osteoprotegerin (OPG), a glycoprotein traditionally implicated in bone remodelling, has been recentl...
Osteoprotegerin ( OPG ) is a key regulator in bone metabolism, that also has effect in vascular syst...
Cardiovascular disease is one of the most frequent causes of mortality and morbidity worldwide. Seve...
International audienceAmong the numerous molecules that are being studied for their potential utilit...
AbstractThe aim of our study was to investigate whether osteoprotegerin (OPG) is related to in-hospi...
The OPG/RANK/RANKL axis is now recognized as a master regulator of bone remodeling, controlling oste...
Osteoprotegerin ( OPG ) is a key regulator in bone metabolism, that also has effect in vascular syst...
ObjectivesWe sought to determine the relationship between osteoprotegerin (OPG) and clinical outcome...
Osteoprotegerin (tnfsf11b, OPG) is a soluble member of the TNF superfamily originally described as a...
Increasing experimental evidence suggests that both tumor necrosis factor (TNF)-related apoptosis-in...
Background—Osteoprotegerin (OPG) is a secretory glycoprotein that belongs to the tumor necrosis fact...
Osteoprotegerin (OPG), receptor activator of nuclear factor-?B ligand (RANKL) and tumor necrosis fac...
PubMed: 22727437The aim of our study was to investigate whether osteoprotegerin (OPG) is related to ...
Osteoprotegerin (OPG) is a glycoprotein that acts as a decoy receptor for receptor activator of nucl...
Osteoprotegerin (OPG) is a 401 amino acid N-glycosylated protein, which is highly expressed in a lar...
Osteoprotegerin (OPG), a glycoprotein traditionally implicated in bone remodelling, has been recentl...
Osteoprotegerin ( OPG ) is a key regulator in bone metabolism, that also has effect in vascular syst...
Cardiovascular disease is one of the most frequent causes of mortality and morbidity worldwide. Seve...
International audienceAmong the numerous molecules that are being studied for their potential utilit...
AbstractThe aim of our study was to investigate whether osteoprotegerin (OPG) is related to in-hospi...
The OPG/RANK/RANKL axis is now recognized as a master regulator of bone remodeling, controlling oste...
Osteoprotegerin ( OPG ) is a key regulator in bone metabolism, that also has effect in vascular syst...
ObjectivesWe sought to determine the relationship between osteoprotegerin (OPG) and clinical outcome...
Osteoprotegerin (tnfsf11b, OPG) is a soluble member of the TNF superfamily originally described as a...
Increasing experimental evidence suggests that both tumor necrosis factor (TNF)-related apoptosis-in...
Background—Osteoprotegerin (OPG) is a secretory glycoprotein that belongs to the tumor necrosis fact...
Osteoprotegerin (OPG), receptor activator of nuclear factor-?B ligand (RANKL) and tumor necrosis fac...
PubMed: 22727437The aim of our study was to investigate whether osteoprotegerin (OPG) is related to ...